#SwingTradingStrategy Parataxis Holdings acquires majority stake in Bridge Biotherapeutics

According to BlockBeats, Parataxis Holdings LLC, a company specializing in digital asset investment, has signed an official agreement to acquire a controlling stake in Bridge Biotherapeutics, Inc. through Parataxis Korea Fund I LLC and its affiliated companies. The investment amounts to up to 25 billion Korean won. Upon completion of the transaction, the company intends to rename itself Parataxis Korea and continue to be listed on KOSDAQ. This agreement is subject to regulatory closing conditions, including shareholder approval.

This acquisition will establish a Bitcoin-focused reserve platform in the South Korean public market, supported by institutional investors with extensive experience in digital asset investment. As part of the deal, Edward Chin, founder and CEO of Parataxis Holdings and co-founder and CEO of Parataxis Capital, will join the company's board of directors. Andrew Kim, a partner at Parataxis Capital, will become the company's CEO and also join the board of directors. James Jungkue Lee, co-founder of Bridge Bio, will continue to lead the core biotechnology division and hold a seat on the board of directors. $BTC